Eduardo Daniel Adelchanow

Eduardo Daniel Adelchanow

Auto-generated profile, based on publicly available information

Eduardo Daniel Adelchanow

Affiliation Department of Oncology, Hospital Nacional Profesor Alejandro Posadas, Morón, Argentina

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BIBoris Itkin
Boris Itkin
AGAgustin Garcia
Agustin Garcia
SSSamanta Straminsky
Samanta Straminsky
EAEduardo Daniel Adelchanow
Eduardo Daniel Adelchanow
MPMatias Pereyra
Matias Pereyra
ABAriel Bardach
Ariel Bardach
The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2= 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2= 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2= 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2= 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.

16 March 2015 in Oncología Clínica
Verified
Journal Article
Open access
PDF file
BBBruno Bustos
Bruno Bustos
EAEduardo Adelchanow
Eduardo Adelchanow
DLDaniel Lewi
Daniel Lewi
MCMaría Pía Coppola
María Pía Coppola
BIBoris Itkin
Boris Itkin
MCMarcelo Corti
Marcelo Corti
El sarcoma de Kaposi (SK) es una neoplasia marcadora de SIDA y al día de la fecha persiste como uno de los tumores más frecuentes en pacientes con diagnóstico de HIV, a pesar de la reducción en su incidencia luego de la instauración de los tratamientos antirretrovirales de gran actividad (TARGA). En la revisión retrospectiva de la experiencia institucional de los pacientes con diagnóstico de SK asociado a HIV, se encontraron 21 que realizaron tratamiento con paclitaxel a una dosis de 130 mg/m2 cada 21 días. La edad media al inicio del tratamiento fue de 43.9 años. Todos habían realizado tratamiento previo con doxorrubicina liposomal y se encontraban recibiendo TARGA. La tasa de respuesta a los 6 meses fue del 62%. A un seguimiento medio de 3.2 años, la duración de la respuesta al paclitaxel observada fue de 13.1 meses. El 15% presentó alguna toxicidad grado 3-4 y no se registraron muertes asociadas al tratamiento. En nuestra experiencia institucional, el uso de paclitaxel en pacientes con SK asociado a HIV que progresaron a doxorrubicina liposomal demostró ser efectivo y con un perfil de toxicidad aceptable. Estos resultados son similares a otros estudios comunicados previamente.